It is clear that diagrams can be useful, particularly in showing more complex manoeuvres, eg inserting suppositories or instilling eye-drops.
What are the effects of written information? The majority of patients receiving written information express favourable attitudes, in some cases over 90%, and even to their treatment as a whole. A somewhat smaller percentage report reading the information, but in most studies this is more than 75%.
Effects on knowledge, compliance and therapeutic outcome have been examined in more than 30 studies. It is clear that knowledge is increased considerably, compliance somewhat less, and therapeutic outcomes are smallest (in four out of seven studies).
Patient information leaflets are to become a normal feature of health care in this country. Their advantages and benefits are evident. But they require careful preparation and the support of oral information at the point of delivery. Within the Association of the British Pharmaceutical Industry (ABPl), and indeed within the pharmaceutical industry throughout Europe, a great deal is happening on the patient information front. Before elaborating on this, however, may I make a personal comment; having been in general practice for many years, and holding the strong belief that one of the most important parts of each consultation is to explain to the patient the purpose and effects of the treatment chosen, I particularly welcome the decision which has been taken by the pharmaceutical industry -certainly Services, 1972 (Accepted 5 October 1989 in the UK, but also throughout most of Europe -to produce patient information leaflets particularly those which are going to be provided in original packs, as package inserts. When I was in practice, for many (though not a11) of my patients, the consultation included, or most often concluded with, the issue of a prescription. I always intended to accompany this with verbal instructions on how the medicine was to be taken, including expected side effects, what I hoped the medicine would do to the illness, and how it would help symptoms. I tried to remember to tell them how often to take the medicine and how much, or how many tablets, and perhaps most important of all, for how long the treatment would be needed. But I often forgot that -even though I was trying to achieve the ideal of always telling patients the information they actually needed; with hindsight I am certain I never achieved this ideal most of the time.
However, I reassured myself that the local pharmacists would give patients at least the basic information about the amount of medicine to be taken, and how often, with additionally a word of caution about possible side effects. Proper labelling, and the use of appropriate cautionary labels, introduced as a mandatory requirement by the Royal Pharmaceutical 0141-0768/90/ 050300-03/$02.00/0 © 1990 The Royal Society of Medicine Society has helped a great deal, but not a lot of information can be included on a label, and only very rarely is additional information given to patients once they have left the dispensing pharmacist.
Because of that, we looked for evidence that printed information leaflets, provided within original packs, might be useful. As a result, we consulted with Professor Charles George of the University of Southampton. He and his colleagues have conducted a number of studies which confirm that even the bestmotivated doctors -and pharmacists -do not always give their patients the information which the patients require and expect, and that printed information leaflets do help.
I believe, therefore, that the arrival of patient information leaflets as package inserts will be greatly welcomed by doctors and patients alike.
The ABPI has a definitive policy towards the practical application of the introduction of patient package inserts; these are set out in two booklets which the ABPI has issued on this particular subject.
The booklets are the product of a working party which was set up in late 1984 to produce a report for the Board of Management of the ABPI on the provision of information to patients on medicines.
These are the terms of reference of the Working Party:
(1) To review the various methods currently in use for providing information on pharmacy and prescription medicines to patients, and to consider any other possible methods. (The answer was not very much, and what there was was haphazard) (2) To consult with interested organizations on the provision of patient information on medicines.
(This was fundamentally important, and has stood us in good stead in Europe -of which more anon) (3) In the light of the above two terms of reference, to advise the Association on the most appropriate method or methodes) for the industry to provide patient information on medicines. (4) To consider any other issues relevant to the provision of such patient information. I cannot over-emphasize the importance of consultation. There is no doubt in my mind that taking many interested parties into our confidence on this particular subject brought dividends in achieving cooperation from all concerned when it came to implementing our final recommendations -and that is applying in Europe, where the EFPIA (the federation of pharmaceutical trade associations within Europe) is closely involved in discussions on a European patient information leaflet policy.
Within the UK the bodies with whom we consulted included all the medical Royal Colleges, the Pharmaceutical Society, the British Medical Association, the General Medical Council, the Department of Health, the Health Education Authority and the Plain English Campaign. We also felt it most important that the voice of the consumers -the patients -should be heard, and various consumer groups were also consulted. Within Europe, we have been closely in touch with BEUC, the European consumer group, and EFPIA has presented examples of model patient information leaflets to the Commission.
As a result of our original consultation, a number of conclusions were reached, and our second round of consultation on the draft recommendations produced further comments. There are 10 main recommendations in the final report, to which reference follows, one by one:
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(1) Written information, as a patient package leaflet, should be given to reinforce and amplify that given by the doctor and pharmacist.
All those responsible for commenting on behalf of prescribing doctors, and of consumer groups, have agreed with the emphasis we have given to this particular recommendation. The primary responsibility is that of the prescriber; the secondaryresponsibilityis that ofthe dispenser; and the tertiary responsibility is that of the producer of the product -the pharmaceutical company concerned.In the context of the consumer protection legislation operating throughout Europe, it is particularly important for all concerned to remember this responsibility; the patient must be given 'reasonable information' about the product.
(2) The leaflet should be included in the original pack, on the introduction of original pack dispensing.
Much the most effective way of ensuring the patient actually receives the leaflet is to include it in the original pack. The industry is now moving inexorably towards comprehensive use oforiginal packs, to facilitate compliance with product liability regulations and to provide tamper evidence. With the experience of Tylanol and other drugs in the United States, and the fear ofsimilar tampering which could occur anywhere in the World, including Europe, tamper proof packaging, which can be provided by original pack dispensing, is recognized by the industry as being far more important than was previously realized. With the introduction of original packs, pharmaceutical companies will be including more and more package inserts as patient information leaflets. The inclusion of a leaflet with the original pack is a major safeguard to ensure that the patient does receive appropriate information.
(3) Information should be as brief and succinct as the leaflet regulations allow and should be in a standardized layout, if appropriate, taking due account of the presentation requirements of the regulations, namely that statutory particulars about the product are kept separate from the balance of the leaflet. This is where we provided additional specific guidance on the format and content ofleaflets, including an illustrative leaflet on the hypothetical product 'Bloggofen'. A leaflet which can be easily read and understood will be far more useful than one which is almost unintelligible. We have in fact gone for a reading age of9 years, which the experts tell us is the level the maximum number of members of the population will be able to read and retain. The emphasis must be to reinforce, maybe to add to, but not replace, information given by the doctor or pharmacist.
One of the most controversial decisions which the ABPI had to take was in deciding what essential facts should be included in a patient leaflet which the patient can understand, and what could safely be excluded.
We had to decide whether it is legally safe to leave out information, particularly about side effects, and we very carefully looked at the existing European directive (75/319) and the UK regulations which followed. The view which prevailed is that the experience gained from the excessively detailed package insert included with oral contraceptives was most unsatisfactory, and that printed patient information must be far simpler, less worrying and easier to understanda view strongly supported by Professor Charles George. An illustrative leaflet produced by the ABPI for a hypothetical product 'Bloggofen' bears a very strong family resemblance to the Southampton leaflets but I would prefer to concentrate now on the individual recommendations rather than the illustrative leaflet. However, its existence has been invaluable in getting leaflets off the ground.
(4) Further consideration should be given to the needs of the blind, and of those who do not understand the language of the country.
Perhaps it goes without saying that those patients who for whatever reason cannot read the leaflet printed in the language ofthe country in which they are living should have special arrangements made for their particular circumstances. I must admit that we have not yet come to definite conclusions within the industry on how this should be done, but I have seen patient information in Braille, and numerous instruction leaflets in different languages are already produced for patients using topical preparations and such medicines as inhalation aerosols -and companies are well used to producing information in appropriate languages for their medicines in third world countries. However, the latest information reaching us is that patients from immigrant communities in this country who cannot read English probably cannot read at all, and will rely on members of the family, or a friend, to convey to them essential information.
(5) The leaflets and additional detailed information should be collated into a compendium for provision to doctors and pharmacists and for reference by patients.
The Data Sheet Compendium published by Data Pharm on behalf of the ABPI, brings together in one volume all the data sheets produced by most of the manufacturing pharmaceutical companies in the UK, whether or not they are members of ABPI. Examples ofsuch compendia ofpatient information leaflets already exists, and in Sweden, for example, the patient information compendium available is already a best-seller. It seems to us essential that doctors and pharmacists should be aware of what the package inserts say without having to break open a pack to read the package insert which is included. The publication of a compendium of patient package inserts therefore seems logical, and I am sure the necessary steps will be taken in the various countries to bring this about. Perhaps not surprisingly, most of the consumer bodies with whom we have discussed this strongly support the concept of a published leaflet compendium.
(6) The leaflet should clearly state that the information contained is limited and that further information can be obtained from other sources, including the doctor and the pharmacist.
This proviso has been included in our latest advice, and allows us to have leaflets, as patient package inserts, which are succinct, the legal requirement for comprehensive information being covered by reference to 'other sources' and to the availability of further information from the doctor (or pharmacist). In the USA legal opinions lean towards the most comprehensive package insert possible, but we have, I believe, managed to convince the US companies with UK subsidiaries that the ABPI guidance -though not acceptable in the USA -will work in the UK. Similarly, it is our belief that the ABPI guidance is compatible with the EC Leaflet Directive 75/319/EEC. Furthermore, we are optimistic that any new directive emanating from the European Commission will be compatible with our guidelines.
(7) Individual manufacturers should be responsible for preparing the information, and should hold the copyright thereof.
Factors including product liability legislation and conformity with the product licence, the data sheet, and any similar literature distributed by a company abroad, make it extremely difficult if not virtually impossible for any organization other than the manufacturer to take responsibility for producing printed information on a specific product. If the manufacturer produces it, the manufacturer should include it in the original pack. This is much the most reliable and economic method of ensuring that every patient receives essential information about their medicines without requiring any special effort on the part of the pharmacist or doctor. It would be possible for such information to be removed at the request of the patient's doctor, although I cannot myself believe that this would ever be necessary if we achieve the succinct and comprehensible text to which I have already referred.
Certainly any such removal of the package insert by the pharmacist would complicate product liability and undermine tamper evidence -the additional safeguard implicit in original pack dispensing to which reference has already been made. Some consumer bodies have expressed the view that patient information leaflets should be produced by independent sourcesbut we do not believe that is either necessary or desirable. (8) The cost of providing information should be borne by the manufacturer.
It followsthat ifthe manufacturer is to take responsibility for the text of the leaflet, the manufacturer should pay for it in the first instance -a view which the industry has accepted, so long as the costs of introducing leaflets is eventually recouped.
In consultation, some outside bodies have commented that the independence of the information would be compromised if it were to be produced and paid for by the industry. We reject that, as we believe our integrity is sincere, but particularly because the next recommendation covers this.
(9) The leaflet should be approved by the appropriate licensing authority at the time of issue of the product licence, or at the five yearly renewal of the product licence.
The Department of Health has accepted that it has a legal obligation to approve leaflets supplied as package inserts, and has agreed with our request that a negative approval system should operate. Several patient information leaflets have now been approved -as it happens, all positively. However, if nothing has been heard from the Department of Health within 21 days after acknowledgment of receipt of submission of a leaflet for approval, it can be deemed to have been approved. (10) The effect of the provision of patient information should be reviewed.
Review of any scheme introducing a new concept is essential, and a review mechanism must be devised to assess the effect of patient information on the lines set out. Who actually does this has yet to be decided, but it seems likely that this will become an accepted responsibility of individual companies.
To conclude, I believe patients should be told a great deal -but not too much -and I am very encouraged that there has been such a positive response from within the pharmaceutical industry to the implementation of a policy of introducing 'patient-friendly' leaflets.
A period 'of flexibility must now be built in to enable companies to change from bulk packaging to packaging for an individual course of treatment or for a one month's supply for a single patient, but my hope is that the majority of medicines prescribed and dispensed 18 months hence will include a patient package insert which reinforces what those who prescribe and those who dispense have already told their patients. I am also reasonably optimistic that the UK view on this is what will eventually prevail in Europe.
